We strive every day to connect our collective talents to find, develop and bring innovative therapies to people living with rare disease.
Mr. Logan is a senior vice president and member of the executive team at Travere Therapeutics. He has led corporate development since March 2018. Prior to Travere Therapeutics, he served as chief business officer at Tracon Pharmaceuticals, an oncology-focused drug development company. At Tracon, Mr. Logan led all strategic, business and corporate development efforts, including the company’s IPO in January 2015. Before joining Tracon, Mr. Logan held senior corporate development roles at biopharmaceutical companies Bird Rock Bio (formerly RuiYi, Inc.) and Anadys Pharmaceuticals, Inc., before its acquisition by Roche. Prior to these roles, Mr. Logan was a member of the corporate business development group at Eli Lilly and Company.
Mr. Logan served as an officer in the US Naval Nuclear Propulsion Program. He received his bachelor’s of science in chemical engineering from the University of Michigan, and an master’s in business administration from the Kellogg School of Management at Northwestern University.